Funding for this research was provided by:
Centers for Disease Control and Prevention (U01 IP000662)
National Institutes of Health (UL1TR000005, UL1 RR024153)
National Institute of Allergy and Infectious Diseases (R01 AI116575)
Received: 10 March 2017
Accepted: 17 January 2018
First Online: 25 January 2018
Ethics approval and consent to participate
: Most data used in the model came from publically available and/or published data; use of this data is exempt from ethics review in the U.S. ExternalRef removed. However some data came from the 4 Pillars cluster randomized trial. In that study, standard informed consent procedures were followed, and trial protocols were approved by institutional review boards of the University of Pittsburgh, Baylor College of Medicine, and the Harris Health System.
: Not applicable.
: Dr. Zimmerman and Dr. Lin have active research grants from Sanofi Pasteur, Merck & Co., Inc., and Pfizer Inc. Dr. Nowalk has received or currently receives grant funding from Merck & Co., Inc., Pfizer, Inc., and MedImmune, LLC. All other authors have no competing interests to disclose.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.